Leukaemia

• Exploring physicians’ perceptions of adherence levels, reasons for non-adherence, and opinions of how to improve adherence in leukaemia patients receiving treatment
• Patient satisfaction in chemotherapy for leukaemia

Acute lymphoblastic leukaemia

• Support in IRB submissions and scientific dissemination in acute lymphoblastic leukaemia
• Burden of refractory acute lymphoblastic leukaemia on patients and caregivers

Acute myeloid leukaemia (AML)

• Global value dossier and e-v@luate platform for a treatment in AML
• Global value dossier, conference poster and medical writing support in AML
• Quality of life analysis in the treatment of AML
• Payer evidence council value communication materials (booklet, slides and Q&A) to inform phase III trial design in AML
• Cost-effectiveness analysis and budget impact analysis for a prognostic and minimal residual genetic tests for AML
• Systematic literature review of healthcare resource utilisation in AML
• Literature review of resource utilisation in AML
• Strategic consulting on AML
• Health-related quality of life in elderly patients with AML: Position paper on an AML treatment for inclusion in a value dossier
• Qualitative research to understand the value of extended overall survival to AML patients

Chronic lymphocytic leukaemia (CLL)

• Utility study in advanced CLL
• Abstract and manuscript on utility study results in CLL
• Payer evidence dossiers for treatments of CLL
• Mixed treatment comparison and training meeting on a global value dossier for a treatment for CLL
• Health state preference study mapping the change over the course of the CLL disease process
• Conference poster on the health state preference study mapping the change over the course of the CLL disease process
• Global value dossier for a treatment in CLL
• Statistical analysis plans and provision of PRO support to the client for their trials of a biological therapy cancer treatment for CLL
• General consultancy agreement to review PRO measures in CLL
• Analysis of PRO data from the CLL registry
• Manuscript on a budget impact model for a cross-indication biosimilar in CLL

Chronic myeloid leukaemia (CML)

• Value dossier support in CML linking myelosuppression with quality of life impact
• Value dossier support in CML linking response to utilities and additional analysis
• Critical review of PRO instruments in CML
• Adverse event to PRO linking in CML
• Manuscript on AE-PRO linking in CML
• Targeted literature review and manuscript on factors associated with adherence in CML
• Development of a link between side effects and PROs in CML – a univariate approach